144 related articles for article (PubMed ID: 18384222)
21. L1CAM expression in cystic mesothelial lesions: a comparison with adenomatoid tumours, well-differentiated papillary mesothelial tumours and malignant mesotheliomas.
Karpathiou G; Casteillo F; Dridi M; Papoudou-Bai A; Dumollard JM; Peoc'h M
Histopathology; 2021 Aug; 79(2):272-274. PubMed ID: 33847416
[No Abstract] [Full Text] [Related]
22. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
23. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
25. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
Cozzi I; Oprescu FA; Rullo E; Ascoli V
Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
[TBL] [Abstract][Full Text] [Related]
26. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
27. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
28. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor alpha and epidermal growth factor receptor in reactive and malignant mesothelial proliferations.
Cai YC; Roggli V; Mark E; Cagle PT; Fraire AE
Arch Pathol Lab Med; 2004 Jan; 128(1):68-70. PubMed ID: 14692808
[TBL] [Abstract][Full Text] [Related]
30. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
[TBL] [Abstract][Full Text] [Related]
31. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.
Lee AF; Gown AM; Churg A
Am J Surg Pathol; 2013 Mar; 37(3):421-6. PubMed ID: 23108021
[TBL] [Abstract][Full Text] [Related]
32. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase.
Tiemann M; Claviez A; Lüders H; Zimmermann M; Schellong G; Dörffel W; Parwaresch R
Mod Pathol; 2005 Nov; 18(11):1440-7. PubMed ID: 16056247
[TBL] [Abstract][Full Text] [Related]
33. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
Ren HZ; Cheung S; Churg A
Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
[TBL] [Abstract][Full Text] [Related]
34. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
35. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
36. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
Lagana SM; Taub RN; Borczuk AC
Arch Pathol Lab Med; 2012 Jul; 136(7):804-9. PubMed ID: 22742553
[TBL] [Abstract][Full Text] [Related]
37. My approach to the diagnosis of mesothelial lesions.
Butnor KJ
J Clin Pathol; 2006 Jun; 59(6):564-74. PubMed ID: 16731600
[TBL] [Abstract][Full Text] [Related]
38. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Attanoos RL; Griffin A; Gibbs AR
Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
[TBL] [Abstract][Full Text] [Related]
39. CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma.
Pinheiro C; Longatto-Filho A; Soares TR; Pereira H; Bedrossian C; Michael C; Schmitt FC; Baltazar F
Diagn Cytopathol; 2012 Jun; 40(6):478-83. PubMed ID: 22619123
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
